DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DMAC DiaMedica Therapeutics Inc.

Trading 06-01 14:02:55 EDT

5.91

-0.08

-1.34%

High6.04	Low5.75	Vol92.02K
Open5.91	D1 Closing5.99	Amplitude4.84%
Mkt Cap318.45M	Tradable Cap194.70M	Total Shares53.88M
T/O541.86K	T/O Rate0.28%	Tradable Shares32.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DMAC","market":"US","secType":"STK","nameCN":"DiaMedica Therapeutics Inc.","latestPrice":5.91,"timestamp":1780336940052,"preClose":5.99,"halted":0,"volume":92019,"delay":0,"changeRate":-0.013355592654424051,"floatShares":32944600,"shares":53882506,"eps":-0.705999,"marketStatus":"Trading","change":-0.08,"latestTime":"06-01 14:02:55 EDT","open":5.91,"high":6.035,"low":5.745,"amount":541858.666488,"amplitude":0.048414,"askPrice":5.92,"askSize":16,"bidPrice":5.91,"bidSize":4,"shortable":3,"etf":0,"ttmEps":-0.705999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1780344000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1544158800000,"exchange":"NASDAQ","adjPreClose":5.99,"postHourTrading":{"tag":"盘后","latestPrice":5.99,"preClose":5.99,"latestTime":"17:41 EDT","volume":9852,"amount":59013.48,"timestamp":1780090881769,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.930263,"impliedVol":2.1434,"impliedVolPercentile":0.8884},"requestUrl":"/m/hq/s/DMAC/wiki","defaultTab":"wiki","newsList":[{"id":"2638636695","title":"DiaMedica Therapeutics to present at Jefferies Global Healthcare Conference 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638636695","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638636695?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:30","pubTimestamp":1779913845,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 at 3:45 p.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on May 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL98GDSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637082354","title":"DiaMedica Therapeutics shareholders re-elect seven directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637082354","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637082354?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:31","pubTimestamp":1779395515,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics held its annual general meeting on May 20, 2026.Shareholders ratified Baker Tilly US, LLP as independent registered public accounting firm for the year ending Dec. 31, 2026, with the board authorized to set the firm’s remuneration.Shareholders backed an amendment to the amended and restated 2019 Omnibus Incentive Plan to increase the share reserve by 3,500,000 shares.Seven incumbent directors were returned to the board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is sole","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL5TXJfW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636836840","title":"DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2636836840","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636836840?lang=en_us&edition=fundamental","pubTime":"2026-05-20 21:05","pubTimestamp":1779282310,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics  said Wednesday that enrollment of its phase 2/3 trial of DM199 to treat patients with acute ischemic stroke has reached 75% of its target of 1,200 patients.The biopharmaceutical company said if it reaches 100% enrollment, it will trigger a planned interim analysis. The company also said it still expects the interim analysis to be completed by the end of 2026.The interim analysis will be conducted by the independent Data Safety Monitoring Board to determine if a sample size re-estimation is recommended for the trial.Shares of DiaMedica rose more than 2% pre-bell Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DMAC","BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636842902","title":"DiaMedica ReMEDy2 stroke trial hits 75% enrollment milestone for interim analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2636842902","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636842902?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:31","pubTimestamp":1779280262,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics reported that its Phase 2/3 ReMEDy2 trial of DM199 in acute ischemic stroke passed 75% of the enrollment needed to trigger a planned interim analysis.Results have not been presented yet; the interim review is expected to be completed before year-end 2026.The analysis is intended to guide the path forward by determining whether the study should expand enrollment or stop early if the treatment is unlikely to show benefit.The trial’s final enrollment target will be set following the interim review, with the company remaining blinded to the underlying findings.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL8GRYBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636429978","title":"DiaMedica Therapeutics Announces 75% Enrollment Milestone in Remedy2 Phase 2/3 Acute Ischemic Stroke Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636429978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636429978?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:30","pubTimestamp":1779280200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUA1R9V46:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247064","title":"DiaMedica Therapeutics CEO joins RBC Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247064","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247064?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:15","pubTimestamp":1778616956,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics scheduled to join 2026 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 19, 2026.CEO Rick Pauls to participate; one-on-one investor meetings planned during conference.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL2lGHlJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633454269","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2633454269","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633454269?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:31","pubTimestamp":1778247093,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Diamedica Therapeutics (DMAC), InfuSystem Holdings (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-154?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-154?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DMAC","BK4581","BLSX","LABU","BLSG","LU0029874061.USD","BK4585","BK4588","BK4139","LU0128526141.USD","XBI","BK4112","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633430447","title":"H.C. Wainwright Keeps Their Buy Rating on Diamedica Therapeutics (DMAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633430447","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633430447?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:56","pubTimestamp":1778237794,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Diamedica Therapeutics, with a price target of $12.00....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-diamedica-therapeutics-dmac-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-diamedica-therapeutics-dmac-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633623432","title":"DiaMedica Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633623432","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633623432?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:22","pubTimestamp":1778235723,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryDiaMedica Therapeutics Inc DMAC.OQ reported a quarterly adjusted loss of 19 cents per share for the quarter ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L0ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633150214","title":"DiaMedica Q1 net, operating income miss estimates; R&D costs to rise moderately","url":"https://stock-news.laohu8.com/highlight/detail?id=2633150214","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633150214?lang=en_us&edition=fundamental","pubTime":"2026-05-07 05:08","pubTimestamp":1778101684,"startTime":"0","endTime":"0","summary":"DiaMedica Q1 net, operating income miss estimates; R&D costs to rise moderatelyOverviewUS biopharmaceutical firm's Q1 adjusted EPS met analyst expectationsQ1 net income and operating income missed ana","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL1N41J1IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633150407","title":"DiaMedica Q1 FY26 net loss widens to $10 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633150407","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633150407?lang=en_us&edition=fundamental","pubTime":"2026-05-07 05:06","pubTimestamp":1778101617,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics posted a net loss of USD 10 million, or USD 0.19 per share, for quarter ended March 31, 2026, versus a net loss of USD 7.7 million, or USD 0.18 per share, a year earlier.R&D spending climbed to USD 8 million from USD 5.7 million, while G&A held flat at USD 2.5 million.Cash, cash equivalents, and investments fell to USD 51.3 million from USD 59.9 million at Dec. 31, 2025; net cash used in operating activities increased to USD 9.1 million from USD 7.1 million.ReMEDy2 Phase 2/3 acute ischemic stroke trial surpassed 70% of required interim enrollment, with interim analysis still planned for 4Q 2026.In preeclampsia, DM199 Phase 2 investigator-sponsored trial Part 1a expansion cohort is enrolling with results expected in 2Q 2026; management reiterated expectation for multiple preeclampsia and fetal growth restriction data readouts through 2027 to inform Phase 3 dose selection.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDLsKhFN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633875157","title":"DiaMedica Therapeutics Inc - Reports $51.3 Mln in Cash and Investments, Runway Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2633875157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633875157?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:30","pubTimestamp":1778099402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLX422E44:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633521631","title":"DiaMedica Therapeutics Q1 Cash & Investments USD 51.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633521631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633521631?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:30","pubTimestamp":1778099402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLX422E44:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633515780","title":"DiaMedica Therapeutics Inc - Remedy2 Phase 2/3 Trial Interim Analysis Planned Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633515780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633515780?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:30","pubTimestamp":1778099402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLX422E44:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633696411","title":"DiaMedica Therapeutics Inc  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633696411","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633696411?lang=en_us&edition=fundamental","pubTime":"2026-05-05 06:01","pubTimestamp":1777932085,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc  expected to post a loss of18cents a share - Earnings Preview DiaMedica Therapeutics Inc DMAC.OQ DMAC.O is expected to  show no change in quarterly revenue when it reports  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H2KD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631163202","title":"Press Release: DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631163202","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631163202?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:32","pubTimestamp":1777552320,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke , today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6 . DiaMedica will host a live conference call on Thursday, May 7 at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results.DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant  form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's webs","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIS","BK4007","LENZ","DMAC","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631632211","title":"DiaMedica Therapeutics updates financial calendar with upcoming quarterly results call","url":"https://stock-news.laohu8.com/highlight/detail?id=2631632211","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631632211?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:30","pubTimestamp":1777552249,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics will release first-quarter fiscal 2026 financial results on May 6, 2026.Management will host conference call on May 7, 2026 at 8:00 a.m. EDT to discuss results and provide business update.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL552Cxr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628275846","title":"Companies Like DiaMedica Therapeutics (NASDAQ:DMAC) Are In A Position To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2628275846","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628275846?lang=en_us&edition=fundamental","pubTime":"2026-04-18 21:08","pubTimestamp":1776517738,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmac/diamedica-therapeutics/news/companies-like-diamedica-therapeutics-nasdaqdmac-are-in-a-po","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmac/diamedica-therapeutics/news/companies-like-diamedica-therapeutics-nasdaqdmac-are-in-a-po","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IYW","QQQ","QQQE","QQQM","NQmain","TQQQ","BK4139","QLD","MNQmain","QID","NVIW.SI","ONEQ","QQQJ","DMAC",".IXIC","FTEC","SQQQ","QDTE","PSQ","GPIQ","QQQA","TQQY","NDX","JEPQ","QQQY","QYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624418625","title":"DiaMedica Therapeutics publishes 2025 annual report, sees cash runway through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2624418625","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624418625?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:24","pubTimestamp":1775075080,"startTime":"0","endTime":"0","summary":"DiaMedica annual report for fiscal year 2025 highlighted continued development of lead candidate DM199 across preeclampsia and acute ischemic stroke programs.Health Canada issued a “No Objection” letter enabling a DiaMedica-sponsored Phase 2 dose-ranging study in early-onset preeclampsia.ReMEDy2 Phase 2/3 pivotal trial in acute ischemic stroke reported improving site activation and enrollment following protocol refinements.Board expansion added Dan O’Connor, citing experience from Ambryx Biopharma acquisition by Johnson & Johnson in 2024.Operating runway guidance reaffirmed through end of 2027, supporting current development plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2LKCS1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","IE0001KFT4U8.USD","LU1732800096.USD","IE00B3T34201.USD","LU1032955483.USD","LU2347655156.SGD","LU2471134523.USD","BK4592","LU0795875086.SGD","LU1261432733.SGD","IE0002270589.USD","LU1023059063.AUD","LU2112291526.USD","IE00BLSP4239.USD","LU1061106388.HKD","LU2089984988.USD","LU0234572021.USD","LU0426412945.USD","LU2471134879.HKD","LU0466842654.USD","LU0432979614.USD","IE0034235303.USD","DMAC","LU2602419157.SGD","IE0002141913.USD","LU1894683348.USD","LU2505996681.GBP","LU0882574055.USD","BK4559","BK4568","IE00B1BXHZ80.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU1585245621.USD","LU0994945656.USD","BK4533","LU0234570918.USD","LU1244550494.USD","LU2468319806.SGD","LU1221951046.USD","IE00B3PB1722.GBP","IE00BDGV0183.EUR","LU1244550221.USD","IE00BSNM7G36.USD","IE0009355771.USD","LU0345769631.USD","BK4534","JNJ","LU1244550577.SGD","LU2750360997.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624054918","title":"DiaMedica Therapeutics announces annual shareholder meeting notice and proxy statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624054918","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624054918?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:08","pubTimestamp":1775074133,"startTime":"0","endTime":"0","summary":"DiaMedica set annual general meeting for May 20, 2026 in Minneapolis, Minnesota.Ballot includes ratification of Baker Tilly US as independent auditor for fiscal 2026.Meeting will also consider amended and restated 2019 omnibus incentive plan, including a 3,500,000-share increase in shares available for issuance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL8pZvjS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.diamedica.com","stockEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.005},{"period":"3month","weight":-0.2465},{"period":"6month","weight":-0.3059},{"period":"1year","weight":0.4296},{"period":"ytd","weight":-0.2475}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.044661},{"month":2,"riseRate":0.75,"avgChangeRate":0.065241},{"month":3,"riseRate":0.125,"avgChangeRate":-0.104653},{"month":4,"riseRate":0.5,"avgChangeRate":0.007808},{"month":5,"riseRate":0.5,"avgChangeRate":0.080466},{"month":6,"riseRate":0.571429,"avgChangeRate":0.181571},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.11728},{"month":8,"riseRate":0.571429,"avgChangeRate":0.048626},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.090818},{"month":10,"riseRate":0.571429,"avgChangeRate":0.039154},{"month":11,"riseRate":0.857143,"avgChangeRate":0.137742},{"month":12,"riseRate":0.571429,"avgChangeRate":0.246007}],"exchange":"NASDAQ","name":"DiaMedica Therapeutics Inc.","nameEN":"DiaMedica Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest DiaMedica Therapeutics Inc.(DMAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"DiaMedica Therapeutics Inc.,DMAC,DiaMedica Therapeutics Inc.股票,DiaMedica Therapeutics Inc.股票老虎,DiaMedica Therapeutics Inc.股票老虎国际,DiaMedica Therapeutics Inc.行情,DiaMedica Therapeutics Inc.股票行情,DiaMedica Therapeutics Inc.股价,DiaMedica Therapeutics Inc.股市,DiaMedica Therapeutics Inc.股票价格,DiaMedica Therapeutics Inc.股票交易,DiaMedica Therapeutics Inc.股票购买,DiaMedica Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest DiaMedica Therapeutics Inc.(DMAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction